Skip to content

UVB Model Validation Study

Single Centre, Subject and Observer Blinded, Placebo Controlled, Cross-over Study of the Effect of Oral Ibuprofen and Topical Hydrocortisone-21-acetate on Ultraviolet Radiation (UVR) Induced Pain and Inflammation in Healthy Volunteers

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01055249
Enrollment
24
Registered
2010-01-25
Start date
2010-01-31
Completion date
Unknown
Last updated
2010-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers, Inflammation, Pain

Keywords

UVB, pain, inflammation, model, healthy volunteers, Ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers

Brief summary

Single centre, subject and observer blinded, placebo controlled, cross-over study of the effect of oral ibuprofen and topical hydrocortisone-21-acetate on ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers conducted in two segments and using an intra-individual comparison of application areas.

Detailed description

Single centre, subject and observer blinded, placebo controlled, cross-over study of the effect of oral ibuprofen and topical hydrocortisone-21-acetate on ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers conducted in two segments and using an intra-individual comparison of application areas. Subjects that signed the informed consent and are eligible to the study will be irradiated on the back to evaluate their individual minimal erythema doses (MEDs). Read out to determine MED will be done within 24 h after UVR. A training session (without study medication) using the MED definition areas will be performed in order to introduce subjects to the testing and rating procedures. Subjects will come in within 14 days of screening to start the first Segment of the study. Eligible subjects will be randomised to receive either: 1. IB 600 mg, applied orally b.i.d., or 2. OP, applied orally b.i.d. Allocation of topical treatment to these areas will be randomly assigned to: 1. PG, 15 μl/cm2 applied topically b.i.d., or 2. HC, 15 μl/cm2 applied topically b.i.d. Defined areas will be irradiated with defined dosages of UVR. Assessment of hyperalgesia to heat and signs of inflammation (erythema, skin temperature) for all areas will be performed. Subjects return within 4 to 11 days to the study site for the second segment of the study. Treatment allocation will be crossed-over and new treatment areas will be selected on the back.

Interventions

DRUGIbuprofen, Hydrocortisone

Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.

DRUGHydrocortisone

Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.

Sponsors

X-pert Med GmbH
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy volunteers

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
Hyperalgesia to heat72 h

Secondary

MeasureTime frame
Erythema, Skin temperature72 h

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026